Objective: To determine the frequency of gestational trophoblastic diseases and gestational tropho- blastic neoplasm, its risk factors and prognosis. Methods: This was a descriptive, cross-sectional study conducted at Civil Hospital, Karachi from March 2015 to September 2015. All cases of gestational trophoblastic disease after necessary inves- tigations like tumour marker b-hCG, ultrasound with classical picture of "bunch of grapes" or "snow storm" pattern and X-ray chest (for lung metastases) under went suction evacuation. In all cases specimen was sent for histopathology to confirm gestational trophoblastic disease. After primary treat- ment, cases were followed with b-hCG till complete remission was achieved. During follow-up, cases were labelled as gestational trophoblastic neoplasm on the basis of International Federation of Gyne- cology and Obstetrics (FIGO) criteria. After risk scoring on World Health Organization (WHO) criteria, chemotherapy was given. Results: Out of 497 pregnant ladies, 40 were cases of gestational trophoblastic disease (8.05%). Frequency/obstetric case was 1.7% and frequency/delivery was 2.1%. Out of 40 cases 13 (32.5%) were cases of gestational trophoblastic neoplasm. Out of 13 cases of gestational trophoblastic neo- plasm 9 (69.23%) were labelled as low-risk and 4 (30.76%) as high-risk cases. All cases achieved complete remission. One case of high-risk group expired. Conclusion: All women with gestational trophoblastic disease must be followed as per recommenda- tion with serum b human chorionic gonadotropin measurement until the levels are undetectable, for early diagnosis and optimum treatment of gestational trophoblastic neoplasm.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.